At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
Illuminate Creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Pilot Study Evaluating the Effectiveness and Tolerability of a Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
In Brief
A Phase 2 clinical trial evaluating Illuminate Cream for Melasma. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The purpose of this research study is to gather information on the effectiveness and tolerability of a novel composition of existing U.S. Food and Drug Administration (FDA) approved topical medications for the treatment of moderate to severe melasma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelasma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionDec 2016
TodayJul 2026
First PostedApr 7, 2016
Enrollment StartMay 15, 2016
Primary CompletionDec 30, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.2 years ago
Interventions
Illuminate Creamdrug
Topical compound applied daily